{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T17:57:18Z","timestamp":1792605438075,"version":"4.5.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T00:00:00Z","timestamp":1772496000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T00:00:00Z","timestamp":1772496000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100009857","name":"Regeneron Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s40120-026-00895-2","type":"journal-article","created":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T17:07:59Z","timestamp":1772557679000},"page":"1043-1064","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Exploring the Lived Experiences of Individuals with Amyotrophic Lateral Sclerosis (ALS): A Qualitative Study and Conceptual Model of Signs, Symptoms, and Functional Impacts"],"prefix":"10.1007","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4951-6476","authenticated-orcid":false,"given":"William B.","family":"Nowell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadine","family":"McGale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oren","family":"Levy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Wilding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phoebe","family":"Heinrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nick C.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinsy A.","family":"Andrews","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Rofail","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,3]]},"reference":[{"issue":"Suppl 15","key":"895_CR1","first-page":"S320","volume":"24","author":"D Hulisz","year":"2018","unstructured":"Hulisz D. Amyotrophic lateral sclerosis: disease state overview. Am J Manag Care. 2018;24(Suppl 15):S320\u20136.","journal-title":"Am J Manag Care"},{"issue":"11","key":"895_CR2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20112616","volume":"20","author":"N Nowicka","year":"2019","unstructured":"Nowicka N, Juranek J, Juranek JK, Wojtkiewicz J. Risk factors and emerging therapies in amyotrophic lateral sclerosis. Int J Mol Sci. 2019;20(11):2616.","journal-title":"Int J Mol Sci"},{"key":"895_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.neubiorev.2019.12.032","volume":"111","author":"JP Rosa Silva","year":"2020","unstructured":"Rosa Silva JP, Santiago J\u00fanior JB, Dos Santos EL, de Carvalho FO, de Fran\u00e7a Costa IMP, Mendon\u00e7a DMF. Quality of life and functional independence in amyotrophic lateral sclerosis: a systematic review. Neurosci Biobehav Rev. 2020;111:1\u201311.","journal-title":"Neurosci Biobehav Rev"},{"issue":"1","key":"895_CR4","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s40035-021-00250-5","volume":"10","author":"X Xu","year":"2021","unstructured":"Xu X, Shen D, Gao Y, et al. A perspective on therapies for amyotrophic lateral sclerosis: can disease progression be curbed? Transl Neurodegener. 2021;10(1):29.","journal-title":"Transl Neurodegener"},{"key":"895_CR5","unstructured":"US Food and Drug Administration. FDA approves treatment of amyotrophic lateral sclerosis associated with a mutation in the SOD1 gene. 2023. https:\/\/www.fda.gov\/drugs\/news-events-human-drugs\/fda-approves-treatment-amyotrophic-lateral-sclerosis-associated-mutation-sod1-gene. Accessed 9 Feb 2026."},{"issue":"12","key":"895_CR6","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1056\/NEJMoa2204705","volume":"387","author":"TM Miller","year":"2022","unstructured":"Miller TM, Cudkowicz ME, Genge A, et al. Trial of antisense oligonucleotide tofersen for SOD1 ALS. N Engl J Med. 2022;387(12):1099\u2013110.","journal-title":"N Engl J Med"},{"key":"895_CR7","unstructured":"US Food and Drug Administration. Patient-focused drug development: selecting, developing, or modifying fit-for-purpose clinical outcome assessments. 2022. https:\/\/www.fda.gov\/media\/159500\/download. Accessed 9 Feb 2026."},{"issue":"4","key":"895_CR8","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1007\/s40120-025-00740-y","volume":"14","author":"D Rofail","year":"2025","unstructured":"Rofail D, Chladek M, Williams B, et al. Advancing future amyotrophic lateral sclerosis medicines by incorporating the patient voice into patient-centered holistic measurement strategies for clinical and real-world studies: results from targeted literature reviews. Neurol Ther. 2025;14(4):1311\u201343.","journal-title":"Neurol Ther"},{"issue":"2","key":"895_CR9","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000209549","volume":"103","author":"E McDool","year":"2024","unstructured":"McDool E, Carlton J, Powell PA, et al. Measuring health-related quality of life in amyotrophic lateral sclerosis: a systematic review and conceptual framework. Neurology. 2024;103(2):e209549.","journal-title":"Neurology"},{"issue":"8","key":"895_CR10","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1111\/j.1524-4733.2009.00603.x","volume":"12","author":"M Rothman","year":"2009","unstructured":"Rothman M, Burke L, Erickson P, Leidy NK, Patrick DL, Petrie CD. Use of existing patient-reported outcome (PRO) instruments and their modification: the ISPOR good research practices for evaluating and documenting content validity for the use of existing instruments and their modification PRO task force report. Value Health. 2009;12(8):1075\u201383.","journal-title":"Value Health"},{"issue":"1","key":"895_CR11","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1037\/qup0000145","volume":"8","author":"J Wright","year":"2021","unstructured":"Wright J, Moghaddam N, Dawson DL. Cognitive interviewing in patient-reported outcome measures: a systematic review of methodological processes. Qual Psychol. 2021;8(1):2\u201329.","journal-title":"Qual Psychol"},{"key":"895_CR12","unstructured":"US Food and Drug Administration. Patient-focused drug development: collecting comprehensive and representative input. 2020. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/patient-focused-drug-development-collecting-comprehensive-and-representative-input. Accessed 9 Feb 2026."},{"issue":"8","key":"895_CR13","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1177\/1362361317718987","volume":"22","author":"F McDougall","year":"2018","unstructured":"McDougall F, Willgoss T, Hwang S, et al. Development of a patient-centered conceptual model of the impact of living with autism spectrum disorder. Autism. 2018;22(8):953\u201369.","journal-title":"Autism"},{"issue":"1","key":"895_CR14","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1186\/s13023-021-02059-x","volume":"16","author":"S Karantzoulis","year":"2021","unstructured":"Karantzoulis S, Heuer K, Sparling N, Teynor M. The patient experience of Wilson disease: a conceptual model based on qualitative research. Orphanet J Rare Dis. 2021;16(1):437.","journal-title":"Orphanet J Rare Dis"},{"issue":"6","key":"895_CR15","doi-asserted-by":"publisher","first-page":"2079","DOI":"10.1007\/s40120-023-00544-y","volume":"12","author":"CA Hartford","year":"2023","unstructured":"Hartford CA, Sherman SA, Karantzoulis S, et al. Experience of daily life with generalized myasthenia gravis: a qualitative investigation and assessment of instrument content validity. Neurol Ther. 2023;12(6):2079\u201399.","journal-title":"Neurol Ther"},{"issue":"3","key":"895_CR16","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1007\/s11764-022-01279-9","volume":"18","author":"I Guillemin","year":"2024","unstructured":"Guillemin I, Darpelly M, Wong B, Ingelg\u00e5rd A, Griebsch I. Development of a disease conceptual model of patient experience with metastatic colorectal cancer: identification of the most salient symptoms and impacts. J Cancer Surviv. 2024;18(3):761\u201371.","journal-title":"J Cancer Surviv"},{"issue":"1","key":"895_CR17","doi-asserted-by":"publisher","first-page":"137","DOI":"10.3233\/JPD-202457","volume":"12","author":"H Staunton","year":"2022","unstructured":"Staunton H, Kelly K, Newton L, et al. A patient-centered conceptual model of symptoms and their impact in early Parkinson\u2019s disease: a qualitative study. J Parkinsons Dis. 2022;12(1):137\u201351.","journal-title":"J Parkinsons Dis"},{"issue":"1","key":"895_CR18","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2023-076992","volume":"14","author":"D Rofail","year":"2024","unstructured":"Rofail D, Somersan-Karakaya S, Choi JY, et al. Thematic analysis to explore patients\u2019 experiences with long COVID-19: a conceptual model of symptoms and impacts on daily lives. BMJ Open. 2024;14(1):e076992.","journal-title":"BMJ Open"},{"issue":"1\u20132","key":"895_CR19","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/S0022-510X(99)00210-5","volume":"169","author":"JM Cedarbaum","year":"1999","unstructured":"Cedarbaum JM, Stambler N, Malta E, et al. The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (phase\u00a0III). J Neurol Sci. 1999;169(1\u20132):13\u201321.","journal-title":"J Neurol Sci"},{"issue":"2","key":"895_CR20","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1191\/1478088706qp063oa","volume":"3","author":"V Braun","year":"2006","unstructured":"Braun V, Clarke V. Using thematic analysis in psychology. Qual Res Psychol. 2006;3(2):77\u2013101.","journal-title":"Qual Res Psychol"},{"issue":"2","key":"895_CR21","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1177\/1098214005283748","volume":"27","author":"DR Thomas","year":"2006","unstructured":"Thomas DR. A general inductive approach for analyzing qualitative evaluation data. Am J Eval. 2006;27(2):237\u201346.","journal-title":"Am J Eval"},{"key":"895_CR22","volume-title":"Research methods in health: investigating health and health services","author":"A Bowling","year":"2009","unstructured":"Bowling A. Research methods in health: investigating health and health services. 3rd ed. Maidenhead: Open University Press; 2009.","edition":"3"},{"key":"895_CR23","doi-asserted-by":"publisher","DOI":"10.4324\/9780203413081","volume-title":"Analyzing qualitative data","author":"A Bryman","year":"2002","unstructured":"Bryman A, Burgess B. Analyzing qualitative data. New York: Routledge; 2002."},{"key":"895_CR24","unstructured":"ATLAS.ti Scientific Software Development GmbH. 24.2.0.32043 ed2023."},{"key":"895_CR25","doi-asserted-by":"publisher","DOI":"10.1186\/1472-6874-9-11","volume":"9","author":"AF Klassen","year":"2009","unstructured":"Klassen AF, Pusic AL, Scott A, Klok J, Cano SJ. Satisfaction and quality of life in women who undergo breast surgery: a qualitative study. BMC Womens Health. 2009;9:11.","journal-title":"BMC Womens Health"},{"issue":"10","key":"895_CR26","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1080\/08870440903194015","volume":"25","author":"JJ Francis","year":"2010","unstructured":"Francis JJ, Johnston M, Robertson C, et al. What is an adequate sample size? Operationalising data saturation for theory-based interview studies. Psychol Health. 2010;25(10):1229\u201345.","journal-title":"Psychol Health"},{"issue":"6","key":"895_CR27","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1007\/s10508-012-0016-6","volume":"41","author":"SL Dworkin","year":"2012","unstructured":"Dworkin SL. Sample size policy for qualitative studies using in-depth interviews. Arch Sex Behav. 2012;41(6):1319\u201320.","journal-title":"Arch Sex Behav"},{"issue":"6","key":"895_CR28","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1093\/intqhc\/mzm042","volume":"19","author":"A Tong","year":"2007","unstructured":"Tong A, Sainsbury P, Craig J. Consolidated criteria for reporting qualitative research (COREQ): a 32-item checklist for interviews and focus groups. Int J Qual Health Care. 2007;19(6):349\u201357.","journal-title":"Int J Qual Health Care"},{"issue":"4","key":"895_CR29","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1001\/jamaneurol.2019.4490","volume":"77","author":"CN Fournier","year":"2020","unstructured":"Fournier CN, Bedlack R, Quinn C, et al. Development and validation of the Rasch-Built Overall Amyotrophic Lateral Sclerosis Disability Scale (ROADS). JAMA Neurol. 2020;77(4):480\u20138.","journal-title":"JAMA Neurol"},{"key":"895_CR30","unstructured":"European Medicines Agency. Guideline on clinical investigation of medicinal products for the treatment of amyotrophic lateral sclerosis (ALS). 2015. www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-clinical-investigation-medicinal-products-treatment-amyotrophic-lateral-sclerosis_en.pdf. Accessed 9 Feb 2026."},{"key":"895_CR31","unstructured":"Food and Drug Administration. Amyotrophic lateral sclerosis: developing drugs for treatment. Guidance for industry. 2019. www.fda.gov\/media\/130964\/download. Accessed 9 Feb 2026."},{"issue":"5","key":"895_CR32","doi-asserted-by":"publisher","DOI":"10.1111\/ene.70171","volume":"32","author":"M Spisto","year":"2025","unstructured":"Spisto M, Moretta P, Senerchia G, et al. Identifying mild behavioral and neurocognitive impairment in amyotrophic lateral sclerosis (MBNI-ALS) provides key prognostic insights. Eur J Neurol. 2025;32(5):e70171.","journal-title":"Eur J Neurol"},{"issue":"14","key":"895_CR33","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1212\/WNL.0b013e318214359f","volume":"76","author":"M Elamin","year":"2011","unstructured":"Elamin M, Phukan J, Bede P, et al. Executive dysfunction is a negative prognostic indicator in patients with ALS without dementia. Neurology. 2011;76(14):1263\u20139.","journal-title":"Neurology"},{"issue":"4","key":"895_CR34","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-025-12971-y","volume":"272","author":"E Finegan","year":"2025","unstructured":"Finegan E, Kleinerova J, Hardiman O, et al. Pseudobulbar affect: clinical associations, social impact and quality of life implications\u2014lessons from PLS. J Neurol. 2025;272(4):266.","journal-title":"J Neurol"},{"issue":"15","key":"895_CR35","doi-asserted-by":"publisher","first-page":"e1370","DOI":"10.1212\/WNL.0000000000006317","volume":"91","author":"C Crockford","year":"2018","unstructured":"Crockford C, Newton J, Lonergan K, et al. ALS-specific cognitive and behavior changes associated with advancing disease stage in ALS. Neurology. 2018;91(15):e1370\u201380.","journal-title":"Neurology"},{"issue":"1","key":"895_CR36","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-34620-y","volume":"13","author":"S Opie-Martin","year":"2022","unstructured":"Opie-Martin S, Iacoangeli A, Topp SD, et al. The SOD1-mediated ALS phenotype shows a decoupling between age of symptom onset and disease duration. Nat Commun. 2022;13(1):6901.","journal-title":"Nat Commun"},{"issue":"1","key":"895_CR37","doi-asserted-by":"publisher","DOI":"10.1186\/s40035-015-0036-y","volume":"4","author":"S Yamashita","year":"2015","unstructured":"Yamashita S, Ando Y. Genotype-phenotype relationship in hereditary amyotrophic lateral sclerosis. Transl Neurodegener. 2015;4(1):13.","journal-title":"Transl Neurodegener"},{"issue":"13","key":"895_CR38","doi-asserted-by":"publisher","DOI":"10.3390\/cells11132066","volume":"11","author":"T Fang","year":"2022","unstructured":"Fang T, Je G, Pacut P, Keyhanian K, Gao J, Ghasemi M. Gene therapy in amyotrophic lateral sclerosis. Cells. 2022;11(13):2066.","journal-title":"Cells"},{"issue":"2","key":"895_CR39","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/s40744-019-0153-7","volume":"6","author":"A Ogdie","year":"2019","unstructured":"Ogdie A, Benjamin Nowell W, Reynolds R, et al. Real-world patient experience on the path to diagnosis of ankylosing spondylitis. Rheumatol Ther. 2019;6(2):255\u201367.","journal-title":"Rheumatol Ther"},{"issue":"1","key":"895_CR40","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s10903-020-01015-4","volume":"23","author":"A Otufowora","year":"2021","unstructured":"Otufowora A, Liu Y, Young H, et al. Sex differences in willingness to participate in research based on study risk level among a community sample of African Americans in north central Florida. J Immigr Minor Health. 2021;23(1):19\u201325.","journal-title":"J Immigr Minor Health"},{"issue":"5","key":"895_CR41","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1136\/jnnp-2014-307654","volume":"86","author":"A Palmieri","year":"2015","unstructured":"Palmieri A, Mento G, Calvo V, et al. Female gender doubles executive dysfunction risk in ALS: a case\u2013control study in 165 patients. J Neurol Neurosurg Psychiatry. 2015;86(5):574\u20139.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"8","key":"895_CR42","doi-asserted-by":"publisher","first-page":"e802","DOI":"10.1212\/WNL.0000000000008869","volume":"94","author":"A Chi\u00f2","year":"2020","unstructured":"Chi\u00f2 A, Moglia C, Canosa A, et al. ALS phenotype is influenced by age, sex, and genetics. Neurology. 2020;94(8):e802\u201310.","journal-title":"Neurology"},{"issue":"2","key":"895_CR43","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1111\/ane.13113","volume":"140","author":"DK Schl\u00fcter","year":"2019","unstructured":"Schl\u00fcter DK, Holland DP, Mills RJ, McDermott CJ, Williams TL, Young CA. Use of coping strategies in MND\/ALS: association with demographic and disease-related characteristics. Acta Neurol Scand. 2019;140(2):131\u20139.","journal-title":"Acta Neurol Scand"}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-026-00895-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-026-00895-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-026-00895-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T14:07:47Z","timestamp":1778681267000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40120-026-00895-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,3]]},"references-count":43,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["895"],"URL":"https:\/\/doi.org\/10.1007\/s40120-026-00895-2","relation":{},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"value":"2193-8253","type":"print"},{"value":"2193-6536","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,3]]},"assertion":[{"value":"6 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"William B. Nowell, Oren Levy, and Nick Patel are employees of Regeneron Pharmaceuticals, Inc., and hold stock in Regeneron Pharmaceuticals, Inc. Nadine McGale, Sarah Wilding, and Phoebe Heinrich are employees of Modus Outcomes, a THREAD company. Jinsy A. Andrews has served as a consultant for AL-S Pharma AG (data safety monitoring board [DSMB]), Amylyx Pharmaceuticals, Biogen, Cytokinetics, Neurosense Therapeutics, Akava, QurAlis (DSMB), Regeneron Pharmaceuticals, Inc., and Sanofi (DSMB); and has received research funding to their institution from The ALS Association, Biogen, Cytokinetics, Corcept Therapeutics, ALS Platform Trial (Biohaven, Clene Inc., Ra Pharmaceuticals, Prilenia Therapeutics, Calico, Denali Therapeutics, and The Montreal General Hospital Foundation), and National Institute of Health\/National Institute of Neurological Disorders and Stroke. Diana Rofail is a full-time employee of Regeneron Pharmaceuticals, Inc., and holds stock in Regeneron Pharmaceuticals, Inc., and Roche.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The Western-Copernicus Group Institutional Review Board\u2019s Affairs Department reviewed the study protocol under the Common Rule and applicable guidance, and approved a request for a waiver of authorization for the use and disclosure of protected health information. Participants were paid a fee in line with fair market value to cover their time taken to participate in the study. This study is reported in accordance with the Consolidated Criteria for Reporting Qualitative Research guidelines [\n                      \n                      ].","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}